Jennifer Lee, Vikram Jog

Mar 20, 2018

Fluidigm said in a filing with the US Securities and Exchange Commission that Jennifer Lee, the company's current vice president, controller, and principal accounting officer, is resigning as of March 29. Vikram Jog, Fluidigm's current chief financial officer, will serve as principal accounting officer in addition to his current role. Jog has served as Fluidigm's CFO since February 2008.

More Like This

Sep 21, 2018

Joseph Jimenez

uBiome has appointed Joseph Jimenez to its board of directors to support the firm's new drug discovery and development efforts. Prior to uBiome, Jimenez served as CEO of Novartis, where he focused on leading global businesses while divesting non-core divisions. Jimenez has a track record of business leadership at several companies, including Clorox, ConAgra, and H.J Heiz. In addition to uBiome's board of directors, Jimenez also serves on the boards of Procter & Gamble and General Motors. In addition, he served on the board of directors at Colgate-Palmolive from 2009 to 2015, and at AstraZeneca from 2002 to 2017.

Sep 20, 2018

Steven Riedmuller

Steven Riedmuller is the new CEO for Maxygen, a service provider for clients in synthetic biology, metabolic engineering, gene therapy, immunotherapy, and gene editing. Riedmuller most recently served as senior director for field applications at Synthetic Genomics. Prior to that, he was VP of engineering and business development at Hudson Robotics.

Sep 20, 2018

Hayden Jeffreys

Hayden Jeffreys has taken on a senior commercial role at Premaitha Health and will be appointed to the company's board in the near future. Most recently, he was the COO of Cambridge Epigenetix, and prior to that, interim CEO of ERBA Diagnostics.

Sep 20, 2018

James Kane

Cell Microsystems has appointed James Kane as th firm's director of sales. Kane will lead commercial activtiy for all engineered and array products. Prior to Cell Microsystems, Kane worked for 10 years selling instruments and consumables at several diagnostic firms, including PacBio and QiaGen, as well as single cell biology applications at Becton Dickinson genomcs and Fluidigm.

Sep 14, 2018

Marco Casarin

Oncimmune has appointed Marco Casarin as General Manager, Oncimmune USA. Casarin previously held a position at Thermo Fisher Scientific. In addition, Casarin has held senior commercial, marketing, and operating roles at Roche Diagnostics and Vela Diagnostics. 

Sep 12, 2018

Bob Petrou

Bob Petrou has been named interim CFO and interim principal financial officer of NantHealth, replacing Paul Holt, whose resignation was effective Sept. 11. He will earn about $36,000 per month under a consulting agreement with the company, NantHealth disclosed in a regulatory filing. Petrou most recently was head of finance for the mobility solutions division of smartphone maker BlackBerry. 

Sep 11, 2018

Christian Marcazzo

The IDBS informatics division of Danaher has hired Christian Marcazzo as vice president and general manager. Marcazzo comes to UK-based IDBS from PerkinElmer Informatics, where he had been VP for analytics and search. In his new role, Marcazzo will be responsible for all profit and loss functions, including developing and executing a business strategy, evaluating growth opportunities, and hiring sales and professional services personnel. Danaher bought IDBS in October 2017.

Sep 11, 2018

Allan Brown, David Matthews

QuantuMDx appointed Allan Brown as chief operating officer and David Matthews as chief financial officer. Brown was previously COO and a board director at Genedrive where he oversaw the launch of the company's PCR-based platform, also called Genedrive, for diagnosing hepatitis C. He previously was at Qiagen and Tepnel Life Sciences. Matthews was previously CFO at Contextual Genomics and was part of the founding team at GenomeDx Biosciences. 

Sep 11, 2018

Kelly Gebo

Kelly Gebo has joined the All of Us Research Program at the National Institutes of Health as chief medical and scientific officer. She is a professor of medicine at Johns Hopkins University and an expert in HIV health services research and HIV clinical outcomes. Gebo holds an MD from Johns Hopkins University School of Medicine and a master's degree in public health from the Johns Hopkins Bloomberg School of Public Health.

Sep 11, 2018

Charles David Allis, Michael Grunstein

Charles David Allis and Michael Grunstein have been awarded the 2018 Albert Lasker Basic Medical Research award for their discoveries showing how gene expression is influenced by the chemical modification of histones. Allis is the Joy and Jack Fishman Professor at Rockefeller University, where he heads the Laboratory of Chromatin Biology and Epigenetics. Grunstein is professor emeritus in the Department of Biological Chemistry at the David Geffen School of Medicine at the University of California, Los Angeles.

Sep 11, 2018

Ave Wrigley, Robert Thong, Julian Coe

British bioinformatics firm Repositive has named three new senior executives. Ave Wrigley has joined as chief technology officer, Robert Thong has been hired as chief business officer, and Julian Coe is the new chief finance and operating officer. Thong and Coe each has leadership experience in genomics, life sciences, and digital health companies, while Wrigley comes from an IT background in the e-commerce, data-driven marketing, and multimedia content management sectors.

Sep 11, 2018

Chitra Nayak

Invitae's board of directors this week expanded the number of members on its board to six members and appointed Chitra Nayak as a member. Nayak most recently served as chief operating officer of the real estate technology company Comfy, which was acquired by Siemens in June. Prior to that, Nayak worked at Funding Circle, an online peer-to-peer lending marketplace, and the cloud computing company Salesforce.com. Nayak will stand for re-election on Invitae's board in 2021.
Sep 11, 2018

Katherine Atkinson

Epic Sciences has appointed Katherine Atkinson as its chief commercial officer, charging her with the development of the firm's global commercial strategy. Atkinson joins Epic with two decades of life science and healthcare experience. Most recently, she served as vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico she worked for Illumina, overseeing numerous teams, including molecular biology/PCR sales, inside sales, Latin America, and most recently global channel partners. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Sep 10, 2018

Jack Challis

Cancer diagnostics shop Lucence Diagnostics appointed Jack Challis its healthcare analytics director. He will be based in San Francisco and will organize Lucence's streams of genomics data, as well as drive collaborations with research institutes and healthcare providers in the US. Challis cofounded CliniCast, which was acquired by Elekta in 2015. 

Sep 10, 2018

Edwin Hendrick

Biocept has appointed Edwin Hendrick as Senior Vice President and Chief Commercial Officer. Hendrick brings 25 years of sales and commercial leadership experience in the healthcare industry, with senior level commercial and operational positions at a variety of diagnostic and healthcare service companies. 

In his most recent position at GenomeDx, Hendrick developed the company's commercial strategy and launched its commercial offering. Prior to GenomeDx he served as executive vice president of sales and marketing at Plus Diagnostics. He also served as an executive with US Labs and led sales and marketing for Ventana Medical Systems after beginning his career in sales for Abbott Laboratories.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.